Abstract: The present invention is a method of inhibiting the replication of an influenza virus by using an antiviral compound to inhibit the binding of an influenza-virus PB2 subunit to an RNA cap. The antiviral compound may be 5-iodo-2-[(3-methyl-4-nitrobenzoyl)amino]benzoic acid; 3,3?-[(4-methylphenyl)methylene]bis(4-hydroxy-2H-chromen-2-one); or 7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H,8Hchromeno[3,4?:5,6]pyrano[3,2-c]chromene-6,8-dione. The aforementioned antiviral compounds have successfully inhibited the replication of influenza virus in vitro and in vivo in mouse models.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
October 6, 2020
Assignee:
Sinoclone Ltd
Inventors:
Bojian Zheng, Shuofeng Yuan, Yi Tsun Richard Kao, Jie Zhou
Abstract: The present invention provides a compound as shown in formula (I), formula (II), or formula (III), which can inhibit the binding of influenza virus PB2 protein to RNA cap and has an anti-influenza effect.
Type:
Application
Filed:
April 12, 2017
Publication date:
May 16, 2019
Applicant:
Sinoclone Ltd.
Inventors:
Bojian ZHENG, Shuofeng YUAN, Richard Yi Tsun KAO, Jie ZHOU